Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul;45(7):1341-1347.
doi: 10.1007/s40618-022-01767-w. Epub 2022 Feb 19.

SARS-CoV-2 vaccine-associated subacute thyroiditis

G Yorulmaz  1 , M Sahin Tekin  2
Affiliations

SARS-CoV-2 vaccine-associated subacute thyroiditis

G Yorulmaz et al. J Endocrinol Invest. 2022 Jul.

Abstract

Purpose: With coronavirus disease 2019 (COVID-19), subacute thyroiditis (SAT) cases are on the rise all over the world. COVID-19 vaccine-associated SAT cases have also been reported. In this article, we present our data on 11 vaccine-associated SAT cases.

Methods: Eleven patients were included in the study. Type of the vaccines patients received, time to the occurrence of SAT after vaccination, symptoms and laboratory findings, treatment given, and response to treatment were evaluated.

Results: The age of patients ranged from 26 to 73. Four of the patients were males, and seven were females. Symptoms of six patients were seen after BNT162b2 Pfizer/BioNTech COVID-19 mRNA vaccine®, and four of them after Coronavac inactivated SARS-CoV-2 vaccine®. In one patient, SAT developed after the first dose of BNT162b2, administered after two doses of Coronavac. The average time to the onset of symptoms was 22 days (15-37) after vaccination.

Conclusions: The fact that both whole virus containing and genetic material containing vaccines cause SAT suggests that the trigger may be viral proteins rather than the whole viral particle. Although corticosteroids are commonly preferred in published vaccine-associated SAT cases, we preferred nonsteroidal anti-inflammatory therapy in our patients for sufficient vaccine antibody response. There is not enough information about whether patients who develop SAT can be revaccinated safely considering the ongoing pandemic. Further research is needed for a conclusion in the treatment and revaccination of these patients.

Keywords: COVID-19; Subacute thyroiditis; Vaccination; mRNA-based vaccines.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to declare.

References

    1. World Health Organization. WHO Director-General’s opening remarks at the media briefing on COVID-19- 11 March 2020. [Internet]. 2020. [cited 2021 Nov 11]. Available from: https://www.who.int/director-general/speeches/detail/who-director-genera...
    1. World Health Organization. Coronavirus disease (COVID-19) pandemic. [Internet]. 2021. [cited 2021 Nov 11]. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019
    1. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271–280.e8. doi: 10.1016/j.cell.2020.02.052. - DOI - PMC - PubMed
    1. Rotondi M, Coperchini F, Ricci G, Denegri M, Croce L, Ngnitejeu ST, et al. Detection of SARS-COV-2 receptor ACE-2 mRNA in thyroid cells: a clue for COVID-19-related subacute thyroiditis. J Endocrinol Invest. 2021;44(5):1085–1090. doi: 10.1007/s40618-020-01436-w. - DOI - PMC - PubMed
    1. Guimataes VC. Subacute and Riedel’s thyroiditis. In: Jameson JL, De Groot LJ, editors. Endocrinology adult and pediatric. 7. Philadelphia: Elsevier Saunders; 2016. pp. 1528–1535.